We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Lipocine Inc is a clinical-stage biopharmaceutical company. It is focused on oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders. The company product TLANDO is an oral testosterone replacement therapy TRT. It also has other produ... Lipocine Inc is a clinical-stage biopharmaceutical company. It is focused on oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders. The company product TLANDO is an oral testosterone replacement therapy TRT. It also has other products in the pipeline such as LPCN 1144 LPCN 1148 and LPCN 1107. Show more
Lipocine Announces Publication and Discussion of LPCN 1148 Manuscript at The Liver Meeting 2024 Editor's Cut Session PR Newswire SALT LAKE CITY, Nov. 18, 2024 SALT LAKE CITY, Nov. 18, 2024...
Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2024 PR Newswire SALT LAKE CITY, Nov. 7, 2024 SALT LAKE CITY, Nov. 7, 2024 /PRNewswire/ -- Lipocine Inc. (NASDAQ:...
Lipocine Announces Distribution and License Agreement with SPC Korea to Commercialize TLANDO® in South Korea PR Newswire SALT LAKE CITY, Oct. 31, 2024 SALT LAKE CITY, Oct. 31, 2024 /PRNewswire/...
Lipocine Announces Positive Oral Brexanolone Quantitative EEG Results PR Newswire SALT LAKE CITY, Oct. 10, 2024 Quantitative Electroencephalogram (qEEG) in healthy subjects administered single...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.035 | -0.695134061569 | 5.035 | 5.23 | 4.63 | 11619 | 4.82341504 | CS |
4 | -0.56 | -10.071942446 | 5.56 | 6.1683 | 4.63 | 26260 | 5.49655515 | CS |
12 | 1.37 | 37.741046832 | 3.63 | 6.1683 | 3.5 | 30097 | 4.96179745 | CS |
26 | -1.29 | -20.5087440382 | 6.29 | 11.79 | 3.5 | 38952 | 6.31130786 | CS |
52 | 2.55 | 104.081632653 | 2.45 | 11.79 | 2.38 | 42598 | 5.67866315 | CS |
156 | -14.72 | -74.645030426 | 19.72 | 32.13 | 2.3101 | 208323 | 14.88358472 | CS |
260 | -2.463 | -33.0028138818 | 7.463 | 41.14 | 2.3101 | 964448 | 23.24099469 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions